Acadia Pharma

ACAD

20.3200.74% ( +0.150 )

Closed: Oct 28, 15:59:59 (EDT)

Current ValuationThe current P/E ratio is 9.13, below the reasonable range, cheaper than 91.19% of the time in the past 1 years, and the industry ranks 26/606, the industry Median -1.93.

9.13xP/E

Stock price$20.17Earnings per share$2.21

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.

021426384

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.

0x30x60x90x120x150x

P/E ratio
Name/Symbol
INCYUSIncyte	14.66x	72.15%	$23.63B
GRFSUSGRIFOLS SA	10.63x	45.10%	$5.57B
ACADUSAcadia Pharma	9.13x	73.21%	$3.48B
NRIXUSNurix Therapeutics	9.89x	191.12%	$2.92B
BVNRYUSBavarian Nordic A/S	12.07x	--	$2.89B
PURRUSHyperliquid Strategies	10.70x	67.60%	$2.74B
ADMAUSAdma Biologics	14.81x	35.42%	$2.50B
AUPHUSAurinia Pharma	7.31x	54.20%	$2.30B
LKFTUSLakefront Biotherapeutics	2.95x	86.45%	$2.04B
ANABUSAnaptysbio	5.66x	1,003.56%	$1.48B
VORUSVor BioPharma	1.84x	89.71%	$1.16B
RIGLUSRigel Pharma	2.93x	83.91%	$944.27M
MGTXUSMeiraGTx	11.43x	122.03%	$902.80M
ABUSUSArbutus Pharma	5.52x	535.59%	$844.87M
IRWDUSIronwood Pharma	4.47x	715.55%	$579.99M
AGENUSAgenus	3.26x	--	$299.39M
QTTBUSQ32 Bio	7.67x	162.04%	$259.29M
CUVLUSClinuvel Pharmaceuticals	11.03x	--	$253.15M
PLXUSProtalix Biotherap	10.76x	400.00%	$203.85M
CGENUSCompugen	5.30x	173.68%	$186.61M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.